Log in

OTCMKTS:IPHYFInnate Pharma Stock Price, Forecast & News

$6.23
0.00 (0.00 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.23
Now: $6.23
$6.23
50-Day Range
$4.90
MA: $6.40
$7.07
52-Week Range
$3.70
Now: $6.23
$8.12
VolumeN/A
Average Volume594 shs
Market Capitalization$489.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. In addition, it offers a commercial-stage product, Lumoxiti, an oncology product for treating hairy cell leukemia. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.
Read More
Innate Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPHYF
Previous SymbolNASDAQ:IPHYF
CUSIPN/A
CIKN/A
Phone33-4-30-30-30-30

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$96.12 million
Book Value$4.23 per share

Profitability

Miscellaneous

Employees195
Market Cap$489.30 million
Next Earnings Date6/9/2020 (Estimated)
OptionableNot Optionable

Receive IPHYF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter.

Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

How has Innate Pharma's stock been impacted by COVID-19 (Coronavirus)?

Innate Pharma's stock was trading at $7.1690 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IPHYF shares have decreased by 13.1% and is now trading at $6.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Innate Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innate Pharma.

When is Innate Pharma's next earnings date?

Innate Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, June 9th 2020. View our earnings forecast for Innate Pharma.

What price target have analysts set for IPHYF?

2 brokerages have issued 12 month price objectives for Innate Pharma's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Innate Pharma's stock price to reach $11.00 in the next year. This suggests a possible upside of 76.6% from the stock's current price. View analysts' price targets for Innate Pharma.

Has Innate Pharma been receiving favorable news coverage?

News stories about IPHYF stock have been trending somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innate Pharma earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutInnate Pharma.

Who are some of Innate Pharma's key competitors?

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the following people:
  • Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)
  • Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)
  • Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)
  • Ms. Laure-Hélène Mercier, Exec. VP, CFO & Member of Exec. Board (Age 41)
  • Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55)

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

How do I buy shares of Innate Pharma?

Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innate Pharma's stock price today?

One share of IPHYF stock can currently be purchased for approximately $6.23.

How big of a company is Innate Pharma?

Innate Pharma has a market capitalization of $489.30 million and generates $96.12 million in revenue each year. Innate Pharma employs 195 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is www.innate-pharma.com.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-4-30-30-30-30 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.